IDEAYA Biosciences (IDYA) Competitors $27.13 -0.36 (-1.30%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. VRNA, RVMD, GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, and AXSMShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Which has more risk and volatility, VRNA or IDYA? Verona Pharma PLC American Depositary Share has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Do institutionals and insiders have more ownership in VRNA or IDYA? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VRNA or IDYA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary Share-36.62% -21.12% -9.07% IDEAYA Biosciences N/A -31.42%-29.45% Do analysts recommend VRNA or IDYA? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 1.92%. IDEAYA Biosciences has a consensus price target of $43.36, suggesting a potential upside of 59.80%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.72 Which has higher earnings and valuation, VRNA or IDYA? Verona Pharma PLC American Depositary Share has higher revenue and earnings than IDEAYA Biosciences. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$221.67M39.48-$173.42M-$0.99-108.03IDEAYA Biosciences$7M339.71-$274.48M-$3.79-7.16 Does the media prefer VRNA or IDYA? In the previous week, Verona Pharma PLC American Depositary Share had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 6 mentions for Verona Pharma PLC American Depositary Share and 4 mentions for IDEAYA Biosciences. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.58 beat IDEAYA Biosciences' score of 0.63 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVerona Pharma PLC American Depositary Share and IDEAYA Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.38B$3.33B$6.13B$10.51BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-7.1721.5085.5226.80Price / Sales339.71415.97585.10183.02Price / CashN/A46.3226.3031.10Price / Book2.219.9713.166.63Net Income-$274.48M-$52.22M$3.30B$276.44M7 Day Performance-0.29%5.50%4.71%2.93%1 Month Performance-0.10%11.76%8.36%9.95%1 Year Performance-7.75%24.76%87.42%39.62% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.1959 of 5 stars$27.13-1.3%$43.36+59.8%-8.3%$2.38B$7M-7.1780VRNAVerona Pharma PLC American Depositary Share1.9204 of 5 stars$106.61-0.1%$109.00+2.2%+234.0%$9.20B$42.28M-107.6930Positive NewsRVMDRevolution Medicines4.2961 of 5 stars$46.07+4.9%$74.64+62.0%-1.6%$8.21B$11.58M-10.24250GRFSGrifols3.8549 of 5 stars$9.93+1.1%$10.30+3.7%+7.7%$6.75B$7.81B8.4923,822Positive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5485 of 5 stars$100.64+1.5%$106.64+6.0%+97.2%$6.59B$130.13M-33.44140RNAAvidity Biosciences2.4989 of 5 stars$42.63-0.7%$68.32+60.3%-2.4%$6.27B$10.90M-11.97190ABVXAbivax2.9339 of 5 stars$83.33+0.6%$102.14+22.6%+786.2%$6.26BN/A0.0061News CoverageAnalyst ForecastLEGNLegend Biotech2.8378 of 5 stars$32.85-1.6%$74.22+125.9%-35.9%$6.16B$627.24M-37.332,609Positive NewsAnalyst ForecastCYTKCytokinetics3.8676 of 5 stars$53.89+6.9%$75.71+40.5%+7.0%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2576 of 5 stars$84.84+4.2%$119.50+40.9%-20.1%$5.87BN/A-17.3140AXSMAxsome Therapeutics4.7956 of 5 stars$117.62+0.7%$177.86+51.2%+38.5%$5.83B$385.69M-23.20380 Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Abivax Alternatives Legend Biotech Alternatives Cytokinetics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
